bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bluebird (BLUE) Upgraded to Buy: What Does It Mean for the Stock?

Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.

FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”

Shares of Bluebird Bio Inc. BLUE, +4.80% fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400 million worth of common stock.

Bluebird Bio's stock falls after proposed public stock offering

bluebird (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

bluebird (BLUE): Strong Industry, Solid Earnings Estimate Revisions

Exelixis

Exelixis has vastly outperformed bluebird bio on the market of late, but will this trend continue?

Better Buy: bluebird bio vs. Exelixis

Bluebird Bio shares tumbled Wednesday after the Food and Drug Administration rejected an application for its Bristol Myers Squibb-partnered cancer treatment, known by the test name bb2121.

Biotech Stock Dives After FDA Rejects Its Bristol-Partnered Cancer Drug

bluebird bio, Inc. (BLUE) CEO Nick Leschly on Q1 2020 Results - Earnings Call Transcript

Bristol-Myers

The pharma giant and the smaller biotech will keep working together on a couple of promising CAR-T cancer therapies.

Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

bluebird bio (BLUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for bluebird bio (BLUE) This Earnings Season?

CRISPR Therapeutics

Who wins in a matchup between these two gene-editing leaders?

Better Buy: Crispr Therapeutics vs. bluebird bio

bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

bluebird bio (BLUE) Catches Eye: Stock Jumps 6%

A major move by the Fed lifted the entire stock market, including this biotech stock.

Why bluebird bio Stock Soared Today

Aerie Pharmaceuticals

Axsome Therapeutics

Biogen

Puma Biotechnology

Pfizer

Rigel Pharmaceuticals

Success in clinical trials doesn't guarantee success on the market.

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Bluebird (BLUE) Down 47.8% Since Last Earnings Report: Can It Rebound?

BioMarin Pharmaceutical

These biopharma stocks are taking a big hit because of the COVID-19 pandemic.

Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday

AnaptysBio

These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.

Why AnaptysBio, bluebird bio, and Exelixis Shares Rebounded Last Friday

Editas Medicine

Worries about a coronavirus impact don't make sense.

Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking Today

bluebird bio presents enticing prospects, but can this biotech stock make you rich?

Is bluebird bio a Millionaire-Making Biotech?

Intuitive Surgical

It's not just their cancer treatments that make these stocks attractive.

3 Cancer Treatment Stocks  to Buy Right Now

bluebird (BLUE) reports a wider-than-expected loss and in-line revenues for the fourth quarter of 2019.

bluebird (BLUE) Q4 Earnings Miss Estimates, Revenues In Line

But there are some things that do matter for the biotech.

Why bluebird bio's Q4 Results Really Don't Matter

This gene-therapy developer delivered decent revenue figures, but its losses continue to grow.

bluebird bio Beats Its Q4 Revenue Target but Misses on EPS

Vertex Pharmaceuticals

A large-cap biotech, a mid-cap biotech, and a small-cap biotech that have one thing in common: great growth prospects.

3  Best Biotech Stocks to Buy for the Next Decade

Gilead Sciences

Growth is a big question mark for both of these stocks, but for very different reasons.

Better Buy:  bluebird bio vs.  Gilead Sciences

Denali Therapeutics

FibroGen

Nektar Therapeutics

Regeneron Pharmaceuticals

The only thing more important than what to buy is what not to buy. These biotech stocks are at the top of the avoid list.

News for bluebird bio Stock (BLUE)